Instil Bio, INC 8-K filings

Instil Bio announced its second quarter 2026 financial results, reporting a reduced net loss per share and an extended cash runway beyond 2027, while also exploring potential acquisitions and in-licensing opportunities.

Instil Bio, Inc. stockholders re-elected Class II directors and ratified the appointment of RSM US LLP as the company's independent auditor for 2026.

Instil Bio reported first quarter 2026 results, highlighting a strategic review for potential acquisitions and in-licensing opportunities, with a cash position expected to fund operations beyond 2027.

Instil Bio, Inc. announced on April 1, 2026, the appointment of RSM US LLP as its new independent registered public accounting firm, replacing Deloitte & Touche LLP.

Instil Bio discontinues AXN-2510, pivots to external innovation and M&A, reporting $76.3M cash to fund operations beyond 2027.

Instil Bio's subsidiary, Axion Bio, Inc., has terminated its License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals, effective January 5, 2026, for ex-China rights to AXN-2510 and AXN-27M.

Instil Bio announced its third quarter 2025 financial results and provided a corporate update, highlighting progress in its AXN-2510 clinical trial and an expected cash runway beyond 2026.

Instil Bio reported its second quarter 2025 financial results, highlighted by the U.S. FDA clearance of its IND for AXN-2510/IMM2510 and anticipated initiation of a U.S. clinical trial before year-end 2025.

Instil Bio's partner, ImmuneOnco, announced promising preliminary safety and efficacy results from its Phase 2 study of IMM2510/AXN-2510 in combination with chemotherapy for first-line advanced non-small cell lung cancer.

Instil Bio, Inc. announced the successful election of Bronson Crouch as a Class I director and the ratification of Deloitte & Touche LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025, during its 2025 Annual Meeting of Stockholders.

Instil Bio and ImmuneOnco announced significant progress in their clinical trials for the bispecific antibody 2510, including on-track enrollment for a Phase 2 NSCLC trial in China and plans for a US Phase 1b/2 trial.

Instil Bio's corporate presentation highlights the potential of AXN-2510, a PD-L1xVEGF bispecific antibody, particularly in NSCLC, and its ongoing clinical trials in collaboration with ImmuneOnco.

Instil Bio announced its Q1 2025 financial results and provided a corporate update, highlighting progress with AXN-2510/IMM2510 clinical trials.

Instil Bio, Inc. has entered into an agreement with Jefferies LLC to sell up to $100 million of its common stock through an 'at-the-market' offering.

Instil Bio announced its Q4 and full year 2024 financial results, highlighting progress with AXN-2510/IMM2510 and providing a corporate update.

Instil Bio announces clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco, including the dosing of the first patient in a Phase 1b/2 clinical trial and plans for a potential first-line NSCLC clinical trial in the second half of 2025.

Instil Bio's subsidiary, Complex Therapeutics LLC, obtained an $85.6 million term loan to refinance existing debt on its Tarzana, California facility.

Instil Bio has licensed a potential best-in-class bispecific antibody and provided a corporate update alongside its third quarter 2024 financial results.

Instil Bio and ImmuneOnco are collaborating on a global registrational strategy for their PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, focusing on first-line non-small cell lung cancer and triple-negative breast cancer.

Instil Bio is closing its Manchester, UK operations, resulting in a workforce reduction and estimated restructuring costs of up to $5.5 million.

Instil Bio's presentation details the potential of their bispecific antibody, SYN-2510, in treating various solid tumors, leveraging a collaboration with ImmuneOnco.

Instil Bio has expanded its pipeline with two in-licensed cancer drugs and secured a 15-year lease for its manufacturing facility, extending its cash runway beyond 2026.

Instil Bio's subsidiary, SynBioTx, has secured an exclusive license from ImmuneOnco for bispecific and monoclonal antibody therapies outside of Greater China, potentially worth up to $2.1 billion.

Instil Bio's subsidiary, Complex Therapeutics LLC, has entered into a 15-year lease agreement with AstraZeneca Pharmaceuticals LP for its Tarzana, CA facility.

Instil Bio held its 2024 Annual Meeting of Stockholders, where shareholders voted on the election of directors and the ratification of the company's independent auditor.

Instil Bio announced its first quarter 2024 financial results, highlighting a reduced net loss and a cash runway extending beyond 2026.

Instil Bio announces the immediate resignation of director Jack B. Nielsen for personal reasons and the appointment of George Matcham, Ph.D. to the Audit Committee.

Instil Bio reported its fourth quarter and full year 2023 financial results, highlighted by a strategic collaboration in China and a focus on new therapeutic candidates.

Instil Bio has granted one-year retention bonuses to its CEO and CFO to incentivize their continued service through February 12, 2025.

Instil Bio is collaborating on preclinical manufacturing feasibility studies for its ITIL-306 program, with no current guidance on the timing of data readouts.